Breaking the mold: Overcoming resistance to immune checkpoint inhibitors

被引：3
|
作者：
Zhao, Menglu [1 ]
Yan, Chun-Yan [1 ]
Wei, Ya-Nan [1 ]
Zhao, Xi-He [1 ]
机构：
[1] China Med Univ, Shengjing Hosp, Dept Clin Oncol, Shenyang 110022, Peoples R China
来源：
ANTIVIRAL RESEARCH | 2023年 / 219卷
基金：
中国国家自然科学基金;
关键词：
PD-L1; Drug resistance; Bispecific antibody; Antibody drug conjugate (ADC); TUMOR MUTATIONAL BURDEN; T-CELLS; ANTITUMOR IMMUNITY; CANCER; IMMUNOTHERAPY; BLOCKADE; EFFICACY; RECEPTOR; PD-L1; EXPRESSION;
D O I：
10.1016/j.antiviral.2023.105720
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Immune checkpoint blockade-based therapies are effective against a sorts of cancers. However, drug resistance is a problem that cannot be ignored. This review intends to elucidate the mechanisms underlying drug tolerance induced by PD-1/PD-L1 inhibitors, as well as to outline proposed mechanism-based combination therapies and small molecule drugs that target intrinsic immunity and immune checkpoints. According to the differences of patients and types of cancer, the optimization of individualized combination therapy will help to enhance PD-1/ PD-L1-mediated immunoregulation, reduce chemotherapy resistance, and provide new ideas for chemotherapyresistant cancer.
引用
收藏
页数：11
相关论文
共 50 条
  • [31] Overcoming immune checkpoint blockade resistance in solid tumors with intermittent ITK inhibition
    Manzhi Zhao
    Ling Li
    Caoimhe H. Kiernan
    Melisa D. Castro Eiro
    Floris Dammeijer
    Marjan van Meurs
    Inge Brouwers-Haspels
    Merel E. P. Wilmsen
    Dwin G. B. Grashof
    Harmen J. G. van de Werken
    Rudi W. Hendriks
    Joachim G. Aerts
    Yvonne M. Mueller
    Peter D. Katsikis
    Scientific Reports, 13
  • [32] MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma
    de Azevedo, Ricardo A.
    Shoshan, Einav
    Whang, Shanzhi
    Markel, Gal
    Jaiswal, Ashvin R.
    Liu, Arthur
    Curran, Michael A.
    Travassos, Luiz R.
    Bar-Eli, Menashe
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [33] Primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma
    Cui, Xiaowen
    Ruan, Minghao
    Li, Yao
    Yang, Cheng
    Zhou, Liuyu
    Zhang, Jin
    Jin, Riming
    Wu, Dong
    Wang, Ruoyu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Treg-mediated acquired resistance to immune checkpoint inhibitors
    Saleh, Reem
    Elkord, Eyad
    CANCER LETTERS, 2019, 457 : 168 - 179
  • [35] Antibiotic Therapy: The Cornerstone of Iatrogenic Resistance to Immune Checkpoint Inhibitors
    Pinato, David J.
    Cortellini, Alessio
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17) : 3089 - +
  • [36] Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors
    Berland, Lea
    Gabr, Zeina
    Chang, Michelle
    Ilie, Marius
    Hofman, Veronique
    Rignol, Guylene
    Ghiringhelli, Francois
    Mograbi, Baharia
    Rashidian, Mohamad
    Hofman, Paul
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [37] Immune Checkpoint Inhibitors
    Haanen, John B. A. G.
    Robert, Caroline
    IMMUNO-ONCOLOGY, 2015, 42 : 55 - 66
  • [38] Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma
    Jalil, Anum
    Donate, Melissa M.
    Mattei, Jane
    CANCER DRUG RESISTANCE, 2024, 7
  • [39] Immune checkpoint inhibitors
    Hui, Enfu
    JOURNAL OF CELL BIOLOGY, 2019, 218 (03): : 740 - 741
  • [40] Immune checkpoint inhibitors
    Kitano, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1305 - S1305
12345